A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.

  title={A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.},
  author={J. Mayadev and W. Brady and Yvonne G. Lin and Diane M. Da Silva and H. Lankes and P. Fracasso and S. Ghamande and K. Moore and H. Pham and K. Wilkinson and V. Kennedy and C. Aghajanian and W. Koh and B. Monk and R. Schilder},
  journal={Journal of Clinical Oncology},
5526Background: The outcome of lymph node positive (LN) cervical cancer (CC) with chemoradiation (CRT) is dismal, especially with involved para-aortic nodes (PAN). The anti-CTLA-4 immune checkpoint... 
Immune check-point in cervical cancer.
P pivotal trials supporting immune check-point inhibitors use in the treatment of CC are presented and published. Expand
Targeted therapy in cervical cancer
In this review, new therapeutic modalities are emerging, including immune checkpoint inhibitors, therapeutic vaccines, antibody-drug conjugates, and others, and the data and potential utility of these approaches are discussed. Expand
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
This review aims to illustrate the state of research in the field of immunotherapy, and in particular, deals with the development of CAR-T cell therapy, which represents a very promising treatment in the hematological field, but is still taking its first tentative steps in solid tumors. Expand
Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
A strong rationale supports the use of immunotherapy to restore the immune response against tumor, considering the elevated rates of PD-L1 expression in up to 80% of cervical cancers. Expand
Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
The biologic rational of immuno-oncology in the treatment of CC is explored and the utility of immune checkpoint inhibitors is explored, including anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4), PD-1, and PD-L1. Expand
Immuno-oncology for Gynecologic Malignancies.
There has been an exponential growth of clinical trials testing immunotherapy approaches, both alone and in combination with chemotherapy and/or targeted agents, in patients with gynecologic cancers. Expand
Immunotherapy for Uterine Cervical Cancer
The results from previous clinical trials in cervical cancer are summarized and the ongoing clinical trials, as well as future directions, are described. Expand
Optimizing immunotherapy for gynecologic cancers.
Improved molecular and immunophenotypic biomarkers to more accurately identify patients who will most benefit from immunotherapeutic approaches are urgently needed as the authors attempt to integrate immune-oncology agents, chemotherapy, targeted therapy, and radiation therapy in the management of gynecologic cancers. Expand
Advances in immunotherapy for cervical cancer.
Immune therapy has broad activity in cervical cancer and can be dramatic and durable, and continued work to find the optimal combination and setting for immunotherapy is ongoing. Expand
Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions
The role of the immune system in development of gynecologic cancers is encompassed and recent data regarding immunotherapy applications in ovarian, uterine, and cervical cancers are highlighted. Expand